Baxter Ventures and MVM Life Science Partners have co-led a round that doubled the total equity funding raised by the patient monitoring device developer since 2011.
US-based biosensor system developer VitalConnect has completed a $33m series C round co-led by Baxter Ventures, the strategic investment unit of medical products maker Baxter International.
The round, which was co-led by healthcare-focused venture capital and private equity firm MVM Life Science Partners, increased VitalConnect’s overall equity funding to approximately $66m since it was founded as Vigilo Networks in 2011.
VitalConnect has created a wearable, adhesive patch-based biosensor system called VitalPatch that allows patients to be remotely monitored by hospitals…
